Modification of the proline residue of TRH enhances biological activity and inhibits degradation.
An analogue of TRH with a modified proline residue (Pyr-His-MepNH2) has been synthesised and evaluated. In CNS, but not endocrine tests the analogue had improved activity compared to TRH and was more resistant to enzymatic degradation. A metabolite of TRH, His-Pro, was without biological activity. It is concluded that the biological actions attributed to TRH are due to the parent tripeptide rather than His-Pro and that these actions can be enhanced by improving the biological stability of TRH.